Objective To observe the efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells combined with pemetrexed or gemcitabine for elderly patients with advanced non-small cell lung cancer cells.Methods 90 cases of elderly patients with advanced non-small cell lung cancer were selected in our hospital and randomly divided into the control group who received pemetrexed or gemcitabine treatment and the study group who underwent biological immune therapy for dendritic cells co-cultured with cytokine-induced killer cells on the basis of the control group, with 45 cases in each group.The curative effects and safety were compared between the two groups.Results The disease control rate in the study group (85.36%) was significantly higher than that in the control group (63.97%) ((x)2=7.95, P0.05).14 cases of thrombocytopenia and 5 cases of severe liver damage had occured in the control group, while 10 cases of thrombocytopenia had occured in the study group, which indicated that the incidence rate of complications in the study group (22.22%) was significantly lower than that in the control group (42.22%) ((x)2=8.94, P0.05).对照组出现14例血小板减少,5例出现肝功能受损严重;研究组出现10例血小板减少,其不良反应发生率(22.22%)明显低于对照组(42.22%)(X2=8.94,P<0.05).结论 相比单一药物化疗治疗,DC-CIK联合培美曲塞或吉西他滨单药化疗能够提高老年晚期非小细胞肺癌患者的临床疗效,可提高疾病控制率,亦能够降低不良反应发生率,安全性较高,值得临床上进一步推广和应用.
展开▼
